ZA200907471B - Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment - Google Patents

Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Info

Publication number
ZA200907471B
ZA200907471B ZA2009/07471A ZA200907471A ZA200907471B ZA 200907471 B ZA200907471 B ZA 200907471B ZA 2009/07471 A ZA2009/07471 A ZA 2009/07471A ZA 200907471 A ZA200907471 A ZA 200907471A ZA 200907471 B ZA200907471 B ZA 200907471B
Authority
ZA
South Africa
Prior art keywords
chr16
chr2
prognosis
markers
diagnosis
Prior art date
Application number
ZA2009/07471A
Other languages
English (en)
Inventor
Simon Stacey
Patrik Sulem
Andrei Manolescu
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of ZA200907471B publication Critical patent/ZA200907471B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ZA2009/07471A 2007-03-26 2009-10-23 Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment ZA200907471B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8625 2007-03-26
IS8648 2007-05-25
PCT/IS2008/000009 WO2008117314A2 (en) 2007-03-26 2008-03-26 Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Publications (1)

Publication Number Publication Date
ZA200907471B true ZA200907471B (en) 2014-03-26

Family

ID=39563444

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/07471A ZA200907471B (en) 2007-03-26 2009-10-23 Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Country Status (13)

Country Link
US (1) US20110117545A1 (enExample)
EP (3) EP2540840A3 (enExample)
JP (1) JP5676245B2 (enExample)
KR (1) KR20090127939A (enExample)
CN (1) CN101874120B (enExample)
AU (1) AU2008231425B2 (enExample)
CA (1) CA2681928A1 (enExample)
EA (1) EA019953B1 (enExample)
IL (1) IL201217A (enExample)
MX (1) MX2009010439A (enExample)
NZ (1) NZ580490A (enExample)
WO (1) WO2008117314A2 (enExample)
ZA (1) ZA200907471B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827314B2 (en) 2003-12-08 2017-11-28 Mars, Incorporated Edible compositions which are adapted for use by a companion animal
DK2458017T3 (en) 2005-11-29 2017-07-03 Cambridge Entpr Ltd Markers for breast cancer
EP2313525A2 (en) 2008-07-07 2011-04-27 Decode Genetics EHF Genetic variants for breast cancer risk assessment
EP2342353A1 (en) * 2008-10-03 2011-07-13 Mars, Incorporated Genetic test for liver copper accumulation in dogs and low copper pet diet
MX2011012913A (es) * 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
US8356023B2 (en) * 2009-07-28 2013-01-15 Ancestry.Com Operations Inc. Collaborative systems and methods for constructing representations of data
EP2721180A4 (en) * 2011-06-16 2015-09-02 Decode Genetics Ehf GENETIC VARIANTS FOR PREDICTING THE RISK OF BREAST CANCER
GB201120989D0 (en) 2011-12-06 2012-01-18 Mars Inc Genetic test
KR101390590B1 (ko) * 2012-06-28 2014-04-30 서울대학교산학협력단 췌장암 재발 예후 예측용 마커 및 이의 용도
EP2968371A4 (en) 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
KR102334702B1 (ko) 2014-09-30 2021-12-06 지네틱 테크놀로지스 리미티드 유방암 발생 위험의 평가 방법
CN109155149A (zh) * 2016-03-29 2019-01-04 瑞泽恩制药公司 遗传变体-表型分析系统和使用方法
CN108588263B (zh) * 2018-06-07 2022-02-01 中国农业科学院烟草研究所 一种用于定位和克隆植物中控制同一性状的双隐性基因的方法
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
US10395772B1 (en) * 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
WO2020117869A1 (en) 2018-12-03 2020-06-11 Tempus Labs Clinical concept identification, extraction, and prediction system and related methods
KR102091790B1 (ko) * 2019-09-02 2020-03-20 주식회사 클리노믹스 피검사자와 생물체 간의 유전자 정보를 이용한 유전적 띠 제공 시스템 및 그 방법
CA3154157A1 (en) 2019-09-13 2021-03-18 23Andme, Inc. Methods and systems for determining and displaying pedigrees
WO2024096618A1 (ko) * 2022-11-02 2024-05-10 주식회사 디시젠 암 발생 위험도 예측 방법
CN116287258B (zh) * 2023-02-23 2025-08-26 清华大学深圳国际研究生院 一种新型分子标志物在乳腺癌诊断或预后评估中的应用
CN119381001A (zh) * 2025-01-02 2025-01-28 四川大学华西医院 一种乳腺癌复发风险的预测方法、装置、设备及存储介质
CN120805003B (zh) * 2025-09-04 2025-12-02 四川大学华西医院 一种基于多阶段动态优化的时序数据突变检测方法、系统和存储介质

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
EP1423535A4 (en) * 2001-08-04 2005-07-06 Whitehead Biomedical Inst HAPLOTYP CARD OF THE HUMAN GENOME AND USES THEREOF
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US9157122B2 (en) * 2004-11-11 2015-10-13 Garvan Institute Of Medical Research Method of diagnosing cancer and reagents therefor
KR101138862B1 (ko) * 2005-02-14 2012-05-14 삼성전자주식회사 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
KR101206028B1 (ko) * 2005-03-05 2012-11-28 삼성전자주식회사 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이
US7858303B2 (en) * 2005-03-14 2010-12-28 Wisconsin Alumni Research Foundation Method of analyzing breast cancer susceptibility and resistance
WO2006121991A2 (en) * 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer

Also Published As

Publication number Publication date
EA019953B1 (ru) 2014-07-30
EP2540840A3 (en) 2013-05-15
EP2527466A2 (en) 2012-11-28
NZ580490A (en) 2012-08-31
AU2008231425A1 (en) 2008-10-02
CA2681928A1 (en) 2008-10-02
WO2008117314A3 (en) 2008-12-18
EP2137324A2 (en) 2009-12-30
IL201217A0 (en) 2010-05-31
EA200970891A1 (ru) 2010-04-30
KR20090127939A (ko) 2009-12-14
AU2008231425B2 (en) 2014-03-20
CN101874120B (zh) 2015-01-14
EP2527466A3 (en) 2013-05-15
US20110117545A1 (en) 2011-05-19
JP2010522555A (ja) 2010-07-08
JP5676245B2 (ja) 2015-02-25
CN101874120A (zh) 2010-10-27
MX2009010439A (es) 2009-10-20
EP2540840A2 (en) 2013-01-02
WO2008117314A2 (en) 2008-10-02
IL201217A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
IL201217A0 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL202292A0 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL210439A0 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
PL2387395T3 (pl) Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
EP2291553A4 (en) SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
IL206079A0 (en) Microrna expression profiling and targeting in peripheral blood in lung cancer
IL200186A0 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
MX2009004522A (es) Variantes de suceptibilidad a cancer en chr8q24.21.
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
IL210504A0 (en) Genetic variants for breast cancer risk assessment
IL217120A0 (en) Single nucleotide polymorphisms in brca1 and diagnostic methods of assessing cancer risk based on the same
EP2024515A4 (en) METHYLATION OF GENES IN THE DIAGNOSIS OF CANCER
GB0922085D0 (en) Cancer diagnosis and treatment
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
PL2101805T3 (pl) Ligandy integryn do stosowania w leczeniu nowotworów
IL216369A0 (en) Carcinoma diagnosis and treatments, based on odc1 genotype
EP2148675A4 (en) ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
GB0901837D0 (en) Cancer diagnosis and treatment
HK1140232A (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ZA200908630B (en) Genetic variants on CHR 5PL2 and 10Q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
BRPI0918844A2 (pt) syngr4 para genes-alvo de terapia e diagnóstico do câncer
HK1142369A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment